About 91.15 per cent of patients treated with the drug were RT-PCR negative by day seven, the company said in a statement.
The drug has also shown efficacy against other viral infections, it added. It will be available on the prescription of a medical specialist for use in hospital/institutional setup.
“The fact that we are able to offer a therapy which significantly reduces viral load when given early on can help in better disease management.
It comes at a much-needed time for patients and we will continue to provide them access to critical therapies in this battle against COVID-19,” Dr Sharvil Patel, Managing Director, Cadila Healthcare Ltd, said in a statement.
In its Phase 3 clinical trials, the therapy showed better clinical improvement in the patients suffering from COVID-19.
Earlier the Phase 2 clinical trials study established the early safety, efficacy and tolerability of Virafin and indicated that Pegylated Interferon alpha-2b had significant statistical clinical impact on the patient suffering from moderate COVID-19 disease by reducing their viral load helping in better disease management such as reduced duration of oxygen support.
Source: IANS
